Community curated by people like you

Liraglutide stories

May 1, 2026

FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding List

FDA announced plans to exclude semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.

May 1, 2026·1 source

00

Top claims

▪The Food and Drug Administration determined there is no clinical need to allow large compounding facilities to make large quantities of medicines from semaglutide
▪Tirzepatide is the ingredient in Eli Lilly's Mounjaro diabetes drug
▪Novo Nordisk and Eli Lilly maintain they have resolved supply shortages that previously justified compounding exemptions

Topics

Eli Lilly Weight management Drug Approval and Clinical Trials Novo Nordisk Lifestyle, Wellness and Nutrition GLP-1 medications Healthcare Policy

Related entities

Tirzepatide Semaglutide